

PUBLICATIONS 2019

SERVICE DE BIOSTATISTIQUE ET D'EPIDEMIOLOGIE

BIOSTATISTICS AND EPIDEMIOLOGY DEPARTMENT

1. Altzerinakou MA, Collette L, Paoletti X. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose. *Journal of the National Cancer Institute*. 2019;111(11):1179-85.
2. Altzerinakou MA, Paoletti X. An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology. *Stat Methods Med Res*. 2019:962280219837737.
3. Antoun S, Bayar MA, Dyevre V, Lanoy E, Smolenschi C, Ducreux M. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. *BMC Cancer*. 2019;19(1):847.
4. Arrieta H, Astrugue C, Regueme S, Durrieu J, Maillard A, Rieger A, Terrebonne E, Laurent C, Maget B, Servent V, Lavau-Denes S, Dauba J, Fonck M, Thiebaut R, Bourdel-Marchasson I. Effects of a physical activity programme to prevent physical performance decline in onco-geriatric patients: a randomized multicentre trial. *J Cachexia Sarcopenia Muscle*. 2019;10(2):287-97.
5. Balleyguier C, Dunant A, Ceugnart L, Kandel M, Chauvet MP, Chereil P, Mazouni C, Henrot P, Rauch P, Chopier J, Zilberman S, Doutriaux-Dumoulin I, Jaffre I, Jalaguier A, Houvenaeghel G, Guerin N, Callonnec F, Chapellier C, Raoust I, Mathieu MC, Rimareix F, Bonastre J, Garbay JR. Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2019;37(11):885-92.
6. Bathily T, Borget I, Rivin Del Campo E, Rivera S, Bourgier C. Partial versus whole breast irradiation: Side effects, patient satisfaction and costs. *Cancer Radiother*. 2019;23(2):83-91.
7. Bayar MA, Ivanova A, Le Teuff G. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method. *Comput Methods Programs Biomed*. 2019;176:211-23.
8. Bayar MA, Le Teuff G, Koenig F, Le Deley MC, Michiels S. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. *Stat Methods Med Res*. 2019:962280219862313.
9. Bayle A, Besse B, Annereau M, Bonastre J. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? *European*

journal of cancer. 2019;113:28-31.

10. Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Melaabi S, Lizard S, De Fraipont F, Longchamp E, Morin F, Zalcmann G, Pignon JP, Cadranel J. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). *Clinical lung cancer*. 2019;20(3):222-30.
11. Beinse G, Tellier V, Charvet V, Deutsch E, Borget I, Massard C, Hollebecque A, Verlingue L. Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2. *JCO clinical cancer informatics*. 2019;3:1-10.
12. Belhechmi S, Michiels S, Paoletti X, Rotolo F. An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error. *Contemp Clin Trials Commun*. 2019;15:100402.
13. Berger E, Castagne R, Chadeau-Hyam M, Bochud M, d'Errico A, Gandini M, Karimi M, Kivimaki M, Krogh V, Marmot M, Panico S, Preisig M, Ricceri F, Sacerdote C, Steptoe A, Stringhini S, Tumino R, Vineis P, Delpierre C, Kelly-Irving M. Multi-cohort study identifies social determinants of systemic inflammation over the life course. *Nat Commun*. 2019;10(1):773.
14. Bertin C, Abbas R, Andrieu V, Michard F, Rioux C, Descamps V, Yazdanpanah Y, Bouscarat F. Illicit massive silicone injections always induce chronic and definitive silicone blood diffusion with dermatologic complications. *Medicine (Baltimore)*. 2019;98(4):e14143.
15. Blanchard P, Auperin A, Pignon JP. Are Individual patient data meta-analyses still needed today in oncology? A discussion focused on Head and Neck oncology. *Acta oncologica*. 2019;58(10):1333-6.
16. Bourgier C, Auperin A, Rivera S, Boisselier P, Petit B, Lang P, Lassau N, Taourel P, Tetreau R, Azria D, Bourhis J, Deutsch E, Vozenin MC. Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. *International journal of radiation oncology, biology, physics*. 2019;104(2):365-73.
17. Brard C, Hampson LV, Gaspar N, Le Deley MC, Le Teuff G. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study. *BMC Med Res Methodol*. 2019;19(1):85.
18. Brard C, Piperno-Neumann S, Delaye J, Brugieres L, Hampson LV, Le Teuff G, Le Deley MC, Gaspar N. Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. *BMJ Open*. 2019;9(5):e025877.

19. Carene D, Tran-Dien A, Lemonnier J, Dalenc F, Levy C, Pierga JY, Jacot W, Canon JL, Richon C, Lacroix L, Caux C, Andre F, Michiels S. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. *Breast cancer research and treatment*. 2019.
20. Castagné R, Chadeau-Hyam M, Karimi M, Stringhini S, Vineis P, Delpierre C, Kelly-Irving M. Social patterning of inflammation over the lifecourse and its relationship with mortality. *European Journal of Public Health*. 2019;29(Supplement_4).
21. Chadeau-Hyam M, Karimi M, Castagné R, Bodinier B, Delpierre C, Kelly-Irving M. A socially patterned Biological Health Score and mortality in Understanding Society and UKBiobank. *European Journal of Public Health*. 2019;29(Supplement_4).
22. Chaltiel D, Adjibade M, Deschamps V, Touvier M, Hercberg S, Julia C, Kesse-Guyot E. Programme National Nutrition Sante - guidelines score 2 (PNNS-GS2): development and validation of a diet quality score reflecting the 2017 French dietary guidelines. *The British journal of nutrition*. 2019;122(3):331-42.
23. Chaltiel D, Julia C, Adjibade M, Touvier M, Hercberg S, Kesse-Guyot E. Adherence to the 2017 French dietary guidelines and adult weight gain: A cohort study. *PLoS Med*. 2019;16(12):e1003007.
24. Chamseddine AN, Ducreux M, Armand JP, Paoletti X, Satar T, Paci A, Mir O. Intestinal bacterial beta-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. *Pharmacol Ther*. 2019;199:1-15.
25. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2019;30(12):2012.
26. Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J, Caramella C, Cassard L, Boselli L, Reiners KS, Pogge von Strandmann E, Rusakiewicz S, Ferrara R, Duchemann B, Naigeon M, Pignon JP, Besse B, Chaput N. Circulating innate immune markers and outcomes in treatment-naive advanced non-small cell lung cancer patients. *European journal of cancer*. 2019;108:88-96.

27. Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Caranana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. *Critical reviews in oncology/hematology*. 2019;134:39-45.
28. Dagnino S, Bodinier B, Grigoryan H, Rappaport SM, Karimi M, Guida F, Polidoro S, Edmands WB, Naccarati A, Fiorito G, Sacerdote C, Krogh V, Vermeulen R, Vineis P, Chadeau-Hyam M. Agnostic Cys34-albumin adductomics and DNA methylation: Implication of N-acetylcysteine in lung carcinogenesis years before diagnosis. *International journal of cancer*. 2019.
29. Dautzier E, Lacas B, Blanchard P, Auperin A, Pignon JP. Response to R. Jayaraj. *Oral oncology*. 2019:104439.
30. Dautzier E, Lacas B, Blanchard P, Le QT, Simon C, Wolf G, Janot F, Horiuchi M, Tobias JS, Moon J, Simes J, Deshmane V, Mazon JJ, Mehta S, Zaktonik B, Tamura M, Moyal E, Licitra L, Fortpied C, Haffty BG, Ghi MG, Gregoire V, Harris J, Bourhis J, Auperin A, Pignon JP. Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. *Oral oncology*. 2019;95:106-14.
31. David C, Divard G, Abbas R, Escoubet B, Chezeli J, Chauveheid MP, Rouzaud D, Boutten A, Papo T, Dehoux M, Sacre K. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease. *Scand J Rheumatol*. 2019:1-5.
32. de la Fouchardiere C, Alghuzlan A, Bardet S, Borget I, Borson Chazot F, Do Cao C, Godbert Y, Leenhardt L, Zerdoud S, Leboulleux S. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF((R)) network review. *Bull Cancer*. 2019;106(9):812-9.
33. Derosa L, Bayar MA, Albiges L, Le Teuff G, Escudier B. A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. *Angiogenesis*. 2019;22(3):383-95.

34. Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2019;37(34):3192-202.
35. Enrico D, Paci A, Chaput N, Karamouza E, Besse B. Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation? *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2019.
36. Ferreira AR, Di Meglio A, Pistilli B, Gbenou AS, El-Mouhebb M, Dauchy S, Charles C, Joly F, Everhard S, Lambertini M, Coutant C, Cottu P, Lerebours F, Petit T, Dalenc F, Rouanet P, Arnaud A, Martin A, Berille J, Ganz PA, Partridge AH, Delalogue S, Michiels S, Andre F, Vaz-Luis I. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2019;30(11):1784-95.
37. Foulon S, Cony-Makhoul P, Guerci-Bresler A, Delord M, Solary E, Monnereau A, Bonastre J, Tubert-Bitter P. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study. *Cancer Med*. 2019;8(6):3296-304.
38. Frazer JK, Li KJ, Galardy PJ, Perkins SL, Auperin A, Anderson JR, Pinkerton R, Buxton A, Gross TG, Michon J, Leverger G, Weinstein HJ, Harrison L, Shiramizu B, Barth MJ, Goldman SC, Patte C, Cairo MS. Excellent outcomes in children and adolescents with CNS(+) Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. *British journal of haematology*. 2019;185(2):374-7.
39. Freeman SC, Fisher D, White IR, Auperin A, Carpenter JR. Identifying inconsistency in network meta-analysis: Is the net heat plot a reliable method? *Stat Med*. 2019;38(29):5547-64.
40. Gatta G, Trama A, Capocaccia R. Epidemiology of rare cancers and inequalities in oncologic outcomes. *Eur J Surg Oncol*. 2019;45(1):3-11.
41. Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel-Vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2019;25(3):946-56.

42. Guigay J, Le Caer H, Ortholan C, Auperin A, Michel C, Mertens C. Treatment of inoperable elderly head and neck cancer patients. *Curr Opin Oncol*. 2019;31(3):152-9.
43. Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, de la Fouchardiere C, Valdes N, Riccardi F, Do Cao C, Bertherat J, Goichot B, Beuschlein F, Drui D, Canu L, Niccoli P, Laboureau S, Tabarin A, Leboulleux S, Calsina B, Libe R, Faggiano A, Schlumberger M, Borson-Chazot F, Mannelli M, Gimenez-Roqueplo AP, Caron P, Timmers H, Fassnacht M, Robledo M, Borget I, Baudin E. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. *The Journal of clinical endocrinology and metabolism*. 2019;104(6):2367-74.
44. Hill C, Schlumberger M. [Both formulas of Levothyrox are not bioequivalent]. *Rev Prat*. 2019;69(6):599-601.
45. Imbimbo M, Maury JM, Garassino M, Girard N. Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. *Eur J Surg Oncol*. 2019;45(1):75-80.
46. Jaki T, Gordon A, Forster P, Bijmens L, Bornkamp B, Brannath W, Fontana R, Gasparini M, Hampson LV, Jacobs T, Jones B, Paoletti X, Posch M, Titman A, Vonk R, Koenig F. Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. *Pharm Stat* 17(5):593-606, Sep/Oct 2018., DOI: <https://doi.org/10.1002/pst.1873>. *Pharm Stat*. 2019;18(3):284-6.
47. Karimi M, Castagne R, Delpierre C, Albertus G, Berger E, Vineis P, Kumari M, Kelly-Irving M, Chadeau-Hyam M. Early-life inequalities and biological ageing: a multisystem Biological Health Score approach in Understanding Society. *Journal of epidemiology and community health*. 2019;73(8):693-702.
48. Lacas B, Bouche O, Etienne PL, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon JP, Lepage C, Ducreux M, Borget I. Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. *Expert Rev Pharmacoecon Outcomes Res*. 2019;19(5):601-8.
49. Lafuma A, Cotte FE, Le Tourneau C, Emery C, Gaudin AF, Torreton E, Gourmelen J, Bonastre J. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries. *Journal of medical economics*. 2019;22(7):698-705.
50. Laine JE, Baltar VT, Stringini S, Gandini M, Chadeau-Hyam M, Kivimaki M, Severi G, Perduca V, Hodge AM, Dugue PA, Giles GG, Milne RL, Barros H, Sacerdote C, Krogh V, Panico S, Tumino R, Goldberg M, Zins M, Delpierre C, Vineis P. Reducing socio-economic inequalities in all-cause mortality: a counterfactual mediation approach. *Int J Epidemiol*. 2019.

51. Leroy L, Satar T, Baldini C, Martin-Romano P, Hollebecque A, Michot JM, Ribrag V, Massard C, Paoletti X, Postel Vinay S. 10PSafety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes? *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2019;30(Suppl 1).
52. Lindsay CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen HJM, Hiltermann TJN, Krebs MG, Loges S, Lopez-Lopez R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria JC, Farace F, Renehan A, Dive C, Besse B, Michiels S. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. *European journal of cancer*. 2019;117:60-8.
53. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2019;37(7):559-69.
54. Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2019;30(2):236-42.
55. Lykoudis PM, Partelli S, Muffatti F, Caplin M, Falconi M, Fusai GK. Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. *Eur J Surg Oncol*. 2019;45(1):46-51.
56. Marant-Micallef C, Shield KD, Vignat J, Clero E, Kesminiene A, Hill C, Rogel A, Vacquier B, Bray F, Laurier D, Soerjomataram I. The risk of cancer attributable to diagnostic medical radiation: Estimation for France in 2015. *International journal of cancer*. 2019;144(12):2954-63.
57. Marec-Berard P, Laurence V, Occean BV, Ray-Coquard I, Linassier C, Corradini N, Collard O, Chaigneau L, Cupissol D, Kerbrat P, Saada-Bouzid E, Delcambre C, Gouin F, Guillemet C, Jimenez M, Lervat C, Gaspar N, Le Deley MC, Brugieres L, Piperno-Neumann S. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years. *Journal of adolescent and young adult oncology*. 2019.
58. Matias M, Baciarello G, Neji M, Di Meglio A, Michiels S, Partridge AH, Bendiane MK, Fizazi K, Ducreux M, Andre F, Vaz-Luis I. Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. *Cancer Med*. 2019;8(5):2535-44.

59. McCrory C, Leahy S, Ribeiro AI, Fraga S, Barros H, Avendano M, Vineis P, Layte R. Maternal educational inequalities in measured body mass index trajectories in three European countries. *Paediatric and perinatal epidemiology*. 2019;33(3):226-37.
60. Meddis A, Latouche A, Zhou B, Michiels S, Fine J. Meta-analysis of clinical trials with competing time-to-event endpoints. *Biometrical journal Biometrische Zeitschrift*. 2019.
61. Michiels S, Wason J. Overestimated treatment effects in randomised phase II trials: What's up doctor? *European journal of cancer*. 2019;123:116-7.
62. Moro-Sibilot D, Cozic N, Perol M, Mazieres J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlesi F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verrielle V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2019;30(12):1985-91.
63. Moya-Plana A, Auperin A, Obongo R, Baglin A, Ferrand FR, Baujat B, Saroul N, Casiraghi O, Vergez S, Herman P, Janot F, Thariat J, Verillaud B, de Gabory L. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. *European journal of cancer*. 2019;123:1-10.
64. Mozgunov P, Jaki T, Paoletti X. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. *J Biopharm Stat*. 2019;29(2):359-77.
65. Navani N, Fisher DJ, Tierney JF, Stephens RJ, Burdett S. The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data. *Chest*. 2019;155(3):502-9.
66. Nicolai N, BIASONI D, Catanzaro MA, Colecchia M, Trama A. Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. *Eur J Surg Oncol*. 2019;45(1):60-6.
67. Orlandi E, Alfieri S, Simon C, Trama A, Licitra L. Treatment challenges in and outside a network setting: Head and neck cancers. *Eur J Surg Oncol*. 2019;45(1):40-5.
68. Papaxanthos-Roche A, Maillard A, Chansel-Debordeaux L, Albert M, Patrat C, Lidove O, Germain DP, Perez P, Lacombe D. Semen and male genital tract characteristics of patients with Fabry disease: the FERTIFABRY multicentre observational study. *Basic Clin Androl*. 2019;29:7.
69. Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, Andre F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2019;30(12):1941-9.

70. Pasquali S, Bonvalot S, Tzanis D, Casali PG, Trama A, Gronchi A. Treatment challenges in and outside a network setting: Soft tissue sarcomas. *Eur J Surg Oncol*. 2019;45(1):31-9.
71. Petit C, Blanchard P, Pignon JP, Lueza B. Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas. *Syst Rev*. 2019;8(1):96.
72. Petrovic D, Haba-Rubio J, de Mestral Vargas C, Kelly-Irving M, Vineis P, Kivimaki M, Nyberg S, Gandini M, Bochud M, Vollenweider P, d'Errico A, Barros H, Fraga S, Goldberg M, Zins M, Steptoe A, Delpierre C, Heinzer R, Carmeli C, Chadeau-Hyam M, Stringhini S. The contribution of sleep to social inequalities in cardiovascular disorders: a multi-cohort study. *Cardiovascular research*. 2019.
73. Randon M, Aragno V, Abbas R, Liang H, Labbe A, Baudouin C. In vivo confocal microscopy classification in the diagnosis of meibomian gland dysfunction. *Eye (Lond)*. 2019;33(5):754-60.
74. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. *Eur J Surg Oncol*. 2019;45(1):67-74.
75. Rigaud C, Auperin A, Jourdain A, Haouy S, Couec ML, Aladjidi N, Gandemer V, Lambliotte A, Plat G, Landman-Parker J, Michon J, Leblanc T, Patte C, Minard-Colin V. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. *Pediatr Blood Cancer*. 2019;66(9):e27873.
76. Rossoni C, Bardet A, Geoerger B, Paoletti X. Sequential or combined designs for Phase I/II clinical trials? A simulation study. *Clinical trials*. 2019;16(6):635-44.
77. Rotolo F, Paoletti X, Burzykowski T, Buyse M, Michiels S. A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. *Stat Methods Med Res*. 2019;28(1):170-83.
78. Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay J, Le Tourneau C, Saada-Bouزيد E, Even C. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. *European journal of cancer*. 2019;121:123-9.
79. Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS. LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. *Clinical lung cancer*. 2019;20(2):66-73.e6.

80. Simon M, Bosset PO, Rouanne M, Benhamou S, Radulescu C, Molinie V, Neuzillet Y, Paoletti X, Lebret T. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. *PLoS One*. 2019;14(2):e0211721.
81. Terrisse S, Karamouza E, Parker CC, Sartor AO, James ND, Pirrie S, Collette L, Tombal BF, Chahoud J, Smeland S, Erikstein B, Pignon JP, Fizazi K, Le Teuff G. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. *JAMA Oncol*. 2019.
82. Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, Deandreis D, Grimaldi S, Lumbroso J, Berdelou A, Hadoux J, Hescot S, Hartl D, Baudin E, Schlumberger M, Leboulleux S. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. *Thyroid*. 2019;29(10):1457-64.
83. Trebuchet A, Julia C, Fezeu L, Touvier M, Chaltiel D, Hercberg S, Galan P, Adjibade M, Kesse-Guyot E. Prospective association between several dietary scores and risk of cardiovascular diseases: Is the Mediterranean diet equally associated to cardiovascular diseases compared to National Nutritional Scores? *American heart journal*. 2019;217:1-12.
84. Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, Andre F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2019;37(14):1169-78.
85. Werbrouck C, Evangelista CCS, Lobon-Iglesias MJ, Barret E, Le Teuff G, Merlevede J, Brusini R, Kergrohen T, Mondini M, Bolle S, Varlet P, Beccaria K, Boddaert N, Puget S, Grill J, Debily MA, Castel D. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG). *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2019;25(22):6788-800.
86. Zordan C, Monteil L, Haquet E, Cordier C, Toussaint E, Roche P, Dorian V, Maillard A, Lhomme E, Richert L, Pasquier L, Akloul L, Taris N, Lacombe D. Evaluation of the template letter regarding the disclosure of genetic information within the family in France. *J Community Genet*. 2019;10(4):489-99.